Akeso wins China approval for gumokimab in ankylosing spondylitis
AI Summary- Akeso received Chinese approval for gumokimab to treat active ankylosing spondylitis.
- June 2026 approval made gumokimab available in China for plaque psoriasis.
- AK111-303 met all pre-specified efficacy endpoints in its pivotal Phase 3 study.